The role of pharmacists in eliminating counterfeit medicines in Nigeria.
drugs
falsified
healthcare
pharmaceuticals
products
substandard
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
02
2023
accepted:
10
07
2023
medline:
8
9
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
epublish
Résumé
Over the years, counterfeit pharmaceuticals have posed immense concerns for global health and patient safety. This menace encompasses various classes of medications. Given the criticality of pharmacists' interventions in drug distribution and supply, this study aimed at exploring their role in the prevention and control of counterfeit pharmaceutical products in Nigeria. A cross-sectional study was undertaken, using questionnaires to collect data from pharmacists across various sectors of pharmacy practice in Nigeria. Face and content validity was undertaken on the study tool prior to data collection. Ethical approval was obtained from the National Institute for Pharmaceutical Research and Development Health Research Ethics Committee, and confidentiality was strictly maintained during data collection process. Data were analyzed using Statistical Package for Social Sciences. Descriptive statistical analysis was undertaken and chi square was used to determine association between socio-demographic characteristics and variables. The responses comprised 205 (52.6%) female and 185 (47.4%) male participants. Almost all the participants (98.4%) agreed that strict enforcement of drug laws can contribute to adequate control of counterfeit medicines in Nigeria, and majority of the study sample (64.7%) indicated that the poor implementation of these laws was a major factor influencing the preponderance of counterfeit medicines in the country. Two-thirds (63.5%) of the participants supported the need for pharmacists to provide adequate education to patients on strategies to identify counterfeit medicines, and a similar proportion (68.0%) were of the opinion that it was the responsibility of pharmacists to ensure that drugs are purchased from credible sources. Findings from this study, in addition to confirming pharmacists' instrumentality in the fight against counterfeit medicines, identified certain context specific factors that can strengthen the regulation, policy and the entire healthcare system. Government and relevant stakeholders can therefore begin to articulate strategic reforms for contextual policy intervention that address medicines' counterfeiting, whilst prioritising pharmacists' role in other critical areas in the healthcare system.
Identifiants
pubmed: 37674683
doi: 10.3389/fpubh.2023.1170929
pmc: PMC10477360
doi:
Substances chimiques
Counterfeit Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1170929Informations de copyright
Copyright © 2023 Adigwe.
Déclaration de conflit d'intérêts
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Law Med. 2006;32(2-3):279-323
pubmed: 16927613
J Eval Clin Pract. 2016 Oct;22(5):699-706
pubmed: 26969559
Res Rep Trop Med. 2014 Apr 24;5:11-22
pubmed: 32669888
Innov Pharm. 2021 Jun 10;12(3):
pubmed: 35601591
Am Health Drug Benefits. 2014 Jun;7(4):216-24
pubmed: 25126373
Clin Infect Dis. 2005 Aug 15;41 Suppl 4:S247-57
pubmed: 16032560
J Pharm Sci. 2011 Nov;100(11):4571-9
pubmed: 21698604
J Am Pharm Assoc (2003). 2021 Jan-Feb;61(1):e93-e98
pubmed: 32471767
East Mediterr Health J. 2020 May 21;26(5):556-564
pubmed: 32538449
Res Social Adm Pharm. 2013 May-Jun;9(3):302-10
pubmed: 22835708
Lancet. 2016 Nov 26;388(10060):2603
pubmed: 27832872
PLoS Med. 2009 Mar 24;6(3):e52
pubmed: 19320538
C R Biol. 2008 Dec;331(12):982-5
pubmed: 19027699
J Am Pharm Assoc (2003). 2012 Mar-Apr;52(2):195-9
pubmed: 22370383
BMJ Open. 2022 Dec 22;12(12):e063433
pubmed: 36549744